HANSOH PHARMA (03692.HK): NDA for HS-20093 in Small Cell Lung Cancer Accepted by NMPA
NewTimeSpace News: On 2 September 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 03692) announced that the marketing authorisation application for HS-20093 for injection, an innovative drug of the Group, has been accepted by the National Medical Products Administration (NMPA) for the treatment of adult patients with small cell lung cancer (SCLC) who have failed prior platinum-based therapy.
According to the announcement, HS-20093 is a B7-H3-targeted antibody-drug conjugate (ADC) independently developed by the Group.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HANSOH PHARMA (03692.HK): Refiles EU Marketing Application for Aumseqa
- Hansoh(03692.HK): EU revokes Aumolertinib approval, EMA resubmission planned
- HANSOH PHARMA (03692.HK): NMPA Accepts NDA for HS-20093, Its B7-H3-Targeting ADC, in Osteosarcoma
- HANSOH PHARMA (03692.HK): HS-20093 Gets Osteosarcoma Priority Review
- HANSOH PHARMA (03692.HK): HS-10374 meets co-primary endpoints in Phase III psoriasis trial
